

Listing of the Claims:

The following Listing of the Claims will replace all prior versions and all prior listings of the claims in the present application:

1-40. (Cancelled)

41. (Presently Amended) A method of restoring NFκB activity in a mammal afflicted with an autoimmune disease resulting from a reduction in NFκB activity, comprising administering to a mammal suspected of suffering from said autoimmune disease a therapeutically effective amount of [an agent] a protein which restores NFκB activity so as to treat said disease in said mammal.

42. (Cancelled herein)

43. (Previously Amended) The method according to claim 42, wherein said protein is selected from the group consisting of: NFκB, NFκB p50, NFκB p52, NFκB p65 and IκB.

44. (Cancelled)

45. (Cancelled)

46. The method according to claim 41, wherein said mammal is a human.

47. The method according to claim 46, wherein said autoimmune disease is an HLA class II-linked disease.

48. (Cancelled)

49 – 65. (Withdrawn)